| ID | Name | Protocol | Sponsor | Status | Phase | Created | Actions |
|---|---|---|---|---|---|---|---|
| 148 | ** Abbott OA M12-011 | AbbVie | Cancelled | 2012-06-22 | Details | ||
| 143 | **Integrium Clinical Reserch Diabetic Foot Ulcer | Unknown | Not Selected | 2012-06-22 | Details | ||
| 150 | **PSI Diabetes Type 2 | Unknown | Cancelled | 2012-06-22 | Details | ||
| 332 | 3-V Bio NASH 005 | 3V2640-CLIN-005 | 3-V Biosciences, Inc. | Done - Archived | 2 | 2019-02-27 | Details |
| 357 | 89 Bio NASH | BIO89-100-002 | 89Bio Ltd. | Done - Archived | Phase 1b | 2020-01-15 | Details |
| 470 | 89bio MASH 131 | BIO89-100-131 | 89Bio Ltd. | Enrollment | 3 | 2024-01-24 | Details |
| 231 | Abbott ADC-US-RES-14137 | ADC-US-RES-14137 | Abbott Diabetes Care | Done - Archived | Device | 2014-12-16 | Details |
| 117 | Abbott Alzheimers 876 | AbbVie | Done - Archived | 2 | 2012-05-07 | Details | |
| 429 | Abbott HbA1c | AbbVie | PI Declined | 2022-05-26 | Details | ||
| 53 | Abbott Osteoarthritis of the Knee 889 | M10-889 | AbbVie | Done - Archived | 2 | 2010-07-28 | Details |
| 167 | Abbott Schizophrenia 608 | AbbVie | Done - Archived | 2 | 2012-10-11 | Details | |
| 176 | Abbott Schizophrenia 765 Ext | M13-765 | AbbVie | Done - Archived | 2 | 2013-02-25 | Details |
| 123 | Abbott Schizophrenia 855 | M10-855 | AbbVie | Done - Archived | 2 | 2012-05-18 | Details |
| 305 | AbbVie Testosterone M16-100 | M16-100 | AbbVie | Done - Archived | 4 | 2017-12-12 | Details |
| 319 | Akcea Ionis TRG ISIS 678354-CS2 | ISIS 678354-CS2 | Akcea Ionis Pharmaceuticals | Done - Archived | 2 | 2018-08-03 | Details |
| 302 | Akcea-Ionis Fatty Liver CS02 | ISIS 703802-CS02 | Akcea Ionis Pharmaceuticals | Done - Archived | 2 | 2017-10-11 | Details |
| 3 | Akros Diabetes 004 | Akros Pharma Inc. | Done - Archived | 2 | 2010-05-21 | Details | |
| 127 | Akros Diabetes 002 | Akros Pharma Inc. | Done - Archived | 2 | 2012-06-08 | Details | |
| 271 | Alder Migraine 006 | ALD403-CLIN-006 | Alder BioPharmaceuticals | Done - Archived | 3 | 2016-07-27 | Details |
| 112 | Allergan Neuropathy 004 | 203818-004 | Allergan | Done - Archived | 3 | 2012-05-03 | Details |
| 62 | Allergan Overactive Bladder 004 | GMA-SXR-09-004 | Allergan | Done - Archived | 3 | 2010-09-21 | Details |
| 397 | Alnylam Mild-Mod HTN 002 | ALN-AGT01-002 | Alnylam Pharmaceuticals, Inc. | Done - Archived | 2 | 2021-10-25 | Details |
| 378 | Alnylam NASH | ALN-HSD-001 | Alnylam Pharmaceuticals, Inc. | PI Declined | 1 | 2020-11-23 | Details |
| 261 | Althea MDD and Anxiety | Althea | Not Selected | 2016-02-01 | Details | ||
| 401 | Altimmune Ext 106 | ALT-801-106 | Altimmune, Inc. | Done - Archived | 1 | 2022-02-24 | Details |
| 434 | Altimmune NASH | Altimmune, Inc. | Not Selected | 2022-09-01 | Details | ||
| 400 | Altimmune Obesity 211 | ALT-801-211 | Altimmune, Inc. | Done - Archived | 2 | 2022-02-24 | Details |
| 394 | Altimmune Obesity/Fatty Liver 105 | ALT-801-105 | Altimmune, Inc. | Done - Archived | 1 | 2021-07-14 | Details |
| 4 | Amarin 0017 | AMR-01-01-0017 | Amarin Pharma | Done - Archived | 3 | 2010-05-21 | Details |
| 109 | Amarin Cholesterol/Cardiovascular 0019 | AMR-0101-0019 | Amarin Pharma | Done - Archived | 3b | 2012-04-25 | Details |
| 497 | Amgen DM2/Obesity | 20210181 | Amgen | Not Selected | 3 | 2024-10-17 | Details |
| 498 | Amgen DM2/Obesity 20210181 | 20210181 | Amgen | Not Selected | 3 | 2024-10-18 | Details |
| 406 | Amgen NAFLD 20200001 | 20200001 | Amgen | Done - Archived | 1 | 2022-04-27 | Details |
| 280 | Amylin Adolescent DM2 H80-MC-GWBQ | H80-MC-GWBQ | Amylin | Done - Archived | 3 | 2016-10-28 | Details |
| 159 | Amylin DM2 BCB120 | BCB120 | Amylin | Done - Archived | 3 | 2012-08-07 | Details |
| 120 | Amylin Symlinpen ADA402 | Amylin | Done - Archived | Market Research | 2012-05-08 | Details | |
| 455 | Apnimed Sleep Apnea | APC-APN-305 | Apnimed, Inc | Pending Closeout | 3 | 2023-07-05 | Details |
| 5 | Arena BLOOM | APD356-010 | Arena Pharmaceuticals, Inc. | Done - Archived | 3 | 2010-05-21 | Details |
| 6 | Arena BLOSSOM 11 | APD351-011 | Arena Pharmaceuticals, Inc. | Done - Archived | 3 | 2010-05-21 | Details |
| 500 | Areti Health | Areti Health | Done - Archived | 2025-03-18 | Details | ||
| 245 | Arisaph Lipids ARI-3037MO-005 | ARI-3037MO-005 | Arisaph Pharmaceuticals | Done - Archived | 2a | 2015-06-23 | Details |
| 474 | Arrowhead 3003 SHASTA-3 | AROAPOC3-3003 | Arrowhead Pharmaceuticals | Follow-up | 3 | 2024-03-12 | Details |
| 488 | Arrowhead 3009 MUIR-3 | AROAPOC3-3009 | Arrowhead Pharmaceuticals | Follow-up | 3 | 2024-07-08 | Details |
| 140 | Arteaus Therapeutics Migraine | Arteaus Therapeutics | Not Selected | 2012-06-21 | Details | ||
| 242 | Assurex MDD ARX1006 | ARX1006 | Assurex Healthcare, Inc | Done - Archived | IV | 2015-05-15 | Details |
| 134 | Astellas OAB | Astellas | Cancelled | 2012-06-21 | Details | ||
| 184 | Astellas Over-active Bladder | Astellas | Not Selected | 2013-07-23 | Details | ||
| 225 | AstraZeneca Asthma D3250C00017 | D3250C00017 | AstraZeneca Pharmaceuticals | PI Declined | 2014-08-27 | Details | |
| 408 | AstraZeneca D1840M00070 | D1840M00070 | AstraZeneca Pharmaceuticals | Done - Archived | Exploratory Study | 2022-05-24 | Details |
| 288 | AstraZeneca D1841C00004 | D1841C00004 | AstraZeneca Pharmaceuticals | Done - Archived | Device | 2017-02-17 | Details |
| 229 | AstraZeneca D5551L00006 | D5551L00006 | AstraZeneca Pharmaceuticals | Done - Archived | IV | 2014-10-07 | Details |
| 227 | AstraZeneca D5553C00002 | D5553C00002 | AstraZeneca Pharmaceuticals | Done - Archived | 3 | 2014-10-06 | Details |
| 228 | AstraZeneca D5553C00003 | D5553C00003 | AstraZeneca Pharmaceuticals | Done - Archived | 3 | 2014-10-06 | Details |
| 7 | AstraZeneca Diabetes 19 | D1690C00019 | AstraZeneca Pharmaceuticals | Done - Archived | 3 | 2010-05-21 | Details |
| 267 | AstraZeneca DM2 D1683C00005 | D1683C00005 | AstraZeneca Pharmaceuticals | Done - Archived | 3 | 2016-07-25 | Details |
| 460 | AstraZeneca FORTUNA D7830C00004 | D7830C00004 | AstraZeneca Pharmaceuticals | Follow-up | 2b | 2023-09-20 | Details |
| 113 | AstraZeneca GAD 006 | AstraZeneca Pharmaceuticals | Done - Archived | 2 | 2012-05-04 | Details | |
| 475 | AstraZeneca HTN D6970C00011 | D6970C00011 | AstraZeneca Pharmaceuticals | Pending Closeout | 2024-03-20 | Details | |
| 441 | AstraZeneca MAD D9230C00002 | D9230C00002 | AstraZeneca Pharmaceuticals | Done - Archived | 1 | 2023-01-20 | Details |
| 73 | AstraZeneca MDD 01 | AstraZeneca Pharmaceuticals | Not Selected | 2b | 2011-02-21 | Details | |
| 121 | AstraZeneca MDD 031 | AstraZeneca Pharmaceuticals | Done - Archived | 2B | 2012-05-14 | Details | |
| 39 | AstraZeneca MDD FLEX 02 | D4130C00002 | AstraZeneca Pharmaceuticals | Done - Archived | 3 | 2010-05-26 | Details |
| 40 | AstraZeneca MDD Rollover 07 | D4130C00007 | AstraZeneca Pharmaceuticals | Done - Archived | 3 | 2010-05-27 | Details |
| 346 | AstraZeneca NASH D5671C00002 | D5671C00002 | AstraZeneca Pharmaceuticals | Done - Archived | 2 | 2019-09-27 | Details |
| 377 | AstraZeneca NASH Phase 1 | D7830C00002 | AstraZeneca Pharmaceuticals | Done - Archived | 1 | 2020-11-19 | Details |
| 416 | AstraZeneca NASH Phase II COSMOS 0001 | D6581C00001 | AstraZeneca Pharmaceuticals | Done - Archived | 2a | 2022-05-24 | Details |
| 387 | AstraZeneca OA/Knee 003 | D5680C00003 | AstraZeneca Pharmaceuticals | Cancelled | 2021-04-26 | Details | |
| 90 | AstraZeneca OIC Ext 08 | AstraZeneca Pharmaceuticals | Cancelled | 3 | 2011-06-13 | Details | |
| 71 | AstraZeneca Opioid Induced Constipation 005 | AstraZeneca Pharmaceuticals | Done - Archived | 3 | 2011-01-24 | Details | |
| 333 | Axcella Hepatic Insufficiency AXA1665-002 | AXA1665-002 | Axcella Health, Inc. | Done - Archived | 2019-02-27 | Details | |
| 299 | Axcella DM2/NAFLD AXA1125 | AXA1125-002 | Axcella Health, Inc. | Done - Archived | 2017-08-22 | Details | |
| 325 | Axcella NAFLD AXA1125-003 | AXA1125-003 | Axcella Health, Inc. | Done - Archived | 2018-10-10 | Details | |
| 483 | Axsome MDD 301 | SOL-MDD-301 | Axsome Therapeutics | Done - Archived | 3 | 2024-05-01 | Details |
| 295 | BBN Infant Formula 001 | BBN-IF-001 | Building Block Nutritionals, LLC | Done - Archived | 2017-08-03 | Details | |
| 210 | BI 1218.22 | 1218.22 | Boehringer Ingelheim Pharmaceuticals, Inc. | Not Selected | 2013-10-10 | Details | |
| 410 | BI 1346-0011 | 1346-0011 | Boehringer Ingelheim Pharmaceuticals, Inc. | Not Selected | 2022-05-24 | Details | |
| 411 | BI 1346-0012 | 1346-0012 | Boehringer Ingelheim Pharmaceuticals, Inc. | Not Selected | 2022-05-24 | Details | |
| 412 | BI 1346-0013 | 1346-0013 | Boehringer Ingelheim Pharmaceuticals, Inc. | Not Selected | 2022-05-24 | Details | |
| 413 | BI 1346-0014 | Boehringer Ingelheim Pharmaceuticals, Inc. | Not Selected | 2022-05-24 | Details | ||
| 495 | BI MASH 1501-0004 | 1501-0004 | Boehringer Ingelheim Pharmaceuticals, Inc. | Follow-up | 2a | 2024-10-14 | Details |
| 486 | BI MASH/NASH 0044 | 1404-0044 | Boehringer Ingelheim Pharmaceuticals, Inc. | Not Selected | 3 | 2024-06-03 | Details |
| 487 | BI MASH/NASH 0064 | 1404-0064 | Boehringer Ingelheim Pharmaceuticals, Inc. | Not Selected | 3 | 2024-06-03 | Details |
| 493 | BI MASH/NASH 0064 Metro | 1404-0064 | Boehringer Ingelheim Pharmaceuticals, Inc. | Cancelled | 3 | 2024-08-15 | Details |
| 472 | BI NASH 1404-0056 | 1404-0056 | Boehringer Ingelheim Pharmaceuticals, Inc. | Follow-up | 3 | 2024-02-01 | Details |
| 492 | BI NASH/MASH 0044Metro | 1404-0044 | Boehringer Ingelheim Pharmaceuticals, Inc. | Cancelled | 3 | 2024-08-15 | Details |
| 447 | BI Obesity/Hepatic 002 | 1466-0002 | Boehringer Ingelheim Pharmaceuticals, Inc. | Done - Archived | 1b | 2023-05-08 | Details |
| 465 | BI Obesity-CVD-CKD 1404-0040 | 1404-0040 | Boehringer Ingelheim Pharmaceuticals, Inc. | Follow-up | 3 | 2023-10-12 | Details |
| 183 | Bio Delivery Sciences DPN | Bio Delivery Sciences | Not Selected | 2 | 2013-07-23 | Details | |
| 481 | BioAge BGE105-005 | BGE105-005 | BioAge Labs, Inc | Pending Closeout | 2 | 2024-04-25 | Details |
| 61 | BioCryst Influenza RELIEF 304 | BioCryst | Cancelled | 3 | 2010-09-16 | Details | |
| 235 | Biodel DM2 3-250 | 3-250 | Biodel, Inc. | Cancelled | 2b | 2015-03-26 | Details |
| 335 | Biogen Schizophrenia 263CS201 | 263CS201 | Biogen | Done - Archived | 2 | 2019-04-01 | Details |
| 356 | Biohaven Anxiety 301 | BHV4157-301 | Biohaven Pharmaceuticals | Cancelled | 2019-12-18 | Details | |
| 466 | Biomea COVALENT-111 Expansion Cohort | Bi01892-1002059-BioF101 | Biomea Fusion | Pending Closeout | 2 | 2023-10-16 | Details |
| 464 | Biomea COVALENT-111 Expansion Cohort Metro | Bi01892-1002059-BioF101 | Biomea Fusion | Done - Archived | 2 | 2023-10-10 | Details |
| 426 | Biomea Fusion DM2 Phase 1 | Covalent-111 | Biomea Fusion | Done - Archived | 1 | 2022-05-26 | Details |
| 72 | BMS DM2/HTN 073 | Bristol Myers Squibb | Done - Archived | 3 | 2011-02-16 | Details | |
| 64 | BMS DM2-HTN 077 | Bristol Myers Squibb | Done - Archived | 3 | 2010-10-21 | Details | |
| 145 | BMS MB102-129 Diabetes | Bristol Myers Squibb | Not Selected | 2012-06-22 | Details | ||
| 87 | BMS MDD CORE 07 | Bristol Myers Squibb | Done - Archived | 2b | 2011-04-06 | Details | |
| 89 | BMS MDD Rollover 10 | Bristol Myers Squibb | Done - Archived | 2011-05-23 | Details | ||
| 132 | BMS Migraine 09 | Bristol Myers Squibb | Cancelled | 2a | 2012-06-21 | Details | |
| 316 | BMS NASH 068 | MB130-068 | Bristol Myers Squibb | Done - Archived | 2b | 2018-04-27 | Details |
| 314 | BMS NASH 069 | MB130-069 | Bristol Myers Squibb | Done - Archived | 2b | 2018-04-20 | Details |
| 82 | Boehringer Ingelheim 1275.1 | Boehringer Ingelheim Pharmaceuticals, Inc. | Not Selected | 2011-04-06 | Details | ||
| 177 | Boehringer Ingelheim 1275.10 | 1275.10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Done - Archived | 3 | 2013-05-07 | Details |
| 50 | Boehringer Ingelheim Black-African American DM2 1218.75 | Boehringer Ingelheim Pharmaceuticals, Inc. | Done - Archived | 2 | 2010-06-29 | Details | |
| 144 | Boehringer Ingelheim Diabetes Type 2 | Boehringer Ingelheim Pharmaceuticals, Inc. | Not Selected | 2012-06-22 | Details | ||
| 83 | Boehringer Ingelheim DM 2 1245.31 Ext | Boehringer Ingelheim Pharmaceuticals, Inc. | Done - Archived | 3 | 2011-04-06 | Details | |
| 102 | Boehringer Ingelheim DM2 1218.83 | 1218.83 | Boehringer Ingelheim Pharmaceuticals, Inc. | Done - Archived | 4 | 2011-11-23 | Details |
| 63 | Boehringer Ingelheim DM2 1245.20 | Boehringer Ingelheim Pharmaceuticals, Inc. | Done - Archived | 3 | 2010-09-24 | Details | |
| 76 | Boehringer Ingelheim DM2 1264.3 | Boehringer Ingelheim Pharmaceuticals, Inc. | Done - Archived | 3 | 2011-03-24 | Details | |
| 326 | Boehringer Schizophrenia 1346-0038 | 1346-0038 | Boehringer Ingelheim Pharmaceuticals, Inc. | Done - Archived | 2 | 2018-11-09 | Details |
| 342 | Boehringer-Ingelheim Schizophrenia 1289-0049 | 1289-0049 | Boehringer Ingelheim Pharmaceuticals, Inc. | Cancelled | 2 | 2019-07-08 | Details |
| 439 | Boston 201 Part B | Boston Pharmaceuticals, Inc | Not Selected | 2022-10-17 | Details | ||
| 391 | Boston Pharmaceuticals NASH 201 | BOS-580-201 | Boston Pharmaceuticals, Inc | Done - Archived | 2a | 2021-05-26 | Details |
| 270 | Braeburn Back Pain HS-16-555 | HS-16-555 | Braeburn Pharmaceuticals | Done - Archived | III | 2016-07-27 | Details |
| 491 | Carmot Obesity-DM2 104 (XC45544) | CT-388-104 (XC45544) | Carmot Therapeutics | Follow-up | 2 | 2024-08-15 | Details |
| 392 | Carmot Therapeutics | Carmot Therapeutics | PI Declined | 2021-06-01 | Details | ||
| 476 | Carmot Thereapeutics CT-388-103 | CT-388-103 | Carmot Therapeutics | Cancelled | 2 | 2024-03-29 | Details |
| 224 | Catalina 30 Day Post Study Follow-up | CRI | Done - Archived | 2014-08-07 | Details | ||
| 136 | Cato Research MDD | Cato Research | Not Selected | 2012-06-21 | Details | ||
| 114 | Cephalon Chronic Pain 3056 | C25608/3056/BP/US | Cephalon | Done - Archived | 3B | 2012-05-04 | Details |
| 409 | Cerevel Schizophrenia 2001 | CVL-231-2001 | Cereval Therapeutics | Done - Archived | 2 | 2022-05-24 | Details |
| 437 | Cerevel Schizophrenia 2003 | CVL-231-2003 | Cereval Therapeutics | Done - Archived | 2 | 2022-10-14 | Details |
| 489 | Cidara Influenza CD388.SQ.2.05 | CD388.SQ.2.05 | Cidara Therapeutics | Pending Closeout | 2b | 2024-07-30 | Details |
| 494 | Cidara Influenza CD388.SQ.2.05Lonestar | CD388.SQ.2.05 | Cidara Therapeutics | Cancelled | 2b | 2024-08-15 | Details |
| 360 | CinCor HTN | CIN-107-121 | CinCor Pharma, Inc | PI Declined | 2 | 2020-04-14 | Details |
| 478 | CMC Magnetics DM2 ALMET C112-CTD2 | C112-CTD2 | CMC Magnetics | Cancelled | 2a | 2024-04-09 | Details |
| 482 | CMC Magnetics DM2 ALMET C112-CTD2 | C112-CTD2 | CMC Magnetics | Not Selected | 2a | 2024-04-25 | Details |
| 458 | Compass MDD 006 | Compass 006 | COMPASS Pathfinder Limited | Follow-up | 3 | 2023-09-13 | Details |
| 444 | Compass MDD 006-DOSING ONLY | COMP 006 | COMPASS Pathfinder Limited | Done - Archived | 3 | 2023-03-15 | Details |
| 103 | ConjuChem DM2 103 | ConjuChem | Done - Archived | 2 | 2012-01-06 | Details | |
| 205 | Covance OA Knee | Unknown | Not Selected | 2 | 2013-09-10 | Details | |
| 393 | Cytodyn NAFLD | CDI-NASH-01 | CytoDyn | Cancelled | 2021-06-01 | Details | |
| 8 | Daiichi HTN 301 | CS8635-A-U301 | Daiichi Sankyo Pharma Development | Done - Archived | 3 | 2010-05-21 | Details |
| 257 | Daiichi Sankyo DS8500-A-U202 | DS8500-A-U202 | Daiichi Sankyo Pharma Development | Done - Archived | 2 | 2015-11-19 | Details |
| 99 | Daiichi Sankyo Neuropathy 201 | DS5565-A-U201 | Daiichi Sankyo Pharma Development | Done - Archived | 2 | 2011-11-04 | Details |
| 84 | Daiichi Sankyo WEL-U-306 | Daiichi Sankyo Pharma Development | Done - Archived | 3b/4 | 2011-04-06 | Details | |
| 107 | Dexcom Glucose Monitoring 0920 | Dexcom, Inc. | Done - Archived | Observational | 2012-04-09 | Details | |
| 255 | DS NAFLD | Daiichi Sankyo Pharma Development | Not Selected | 2015-10-22 | Details | ||
| 276 | DS102A-02 NAFLD | DS Biopharma | Not Selected | 2016-10-13 | Details | ||
| 218 | Eisai APD356-G000-401 | APD356-G000-401 | Eisai, Inc. | Not Selected | 2014-02-27 | Details | |
| 246 | Elcelyx Therapeutics, Inc. DM2 LCRM112 | LCRM112 | Elcelyx Therapeutics, Inc. | Done - Archived | 2 | 2015-06-23 | Details |
| 353 | Enanta NASH 102 | EDP 305-102 | Enanta Pharmaceuticals | PI Declined | 2b | 2019-12-18 | Details |
| 317 | Enanta NASH EDP 305-101 | EDP 305-101 | Enanta Pharmaceuticals | Done - Archived | 2 | 2018-05-01 | Details |
| 85 | Endo Chronic Pain 202 | Endo Pharmaceuticals, Inc | Cancelled | 2011-04-06 | Details | ||
| 1 | Endo Low Back Pain 201 | EN3324-201 | Endo Pharmaceuticals, Inc | Done - Archived | 2b | 2010-05-10 | Details |
| 163 | Endo Low Back Pain 307 | EN3409-307 | Endo Pharmaceuticals, Inc | Done - Archived | 3 | 2012-09-10 | Details |
| 125 | Endo Low Back Pain 308 | EN3409-308 | Endo Pharmaceuticals, Inc | Done - Archived | 3 | 2012-05-30 | Details |
| 48 | Envivo Alzheimers 6124 | EVP-1624-010 | Envivo Pharmaceuticals | Done - Archived | 2 | 2010-06-28 | Details |
| 135 | EnVivo Schizophrenia 016 | EVP-6124-016 | Envivo Pharmaceuticals | Done - Archived | 3 | 2012-06-21 | Details |
| 165 | Envivo Schizophrenia Ext 017 | Envivo Pharmaceuticals | Done - Archived | 3 | 2012-10-05 | Details | |
| 186 | Esperion Hypercholesterolemia 008 | 1002-008 | Esperion Therapeutics, Inc. | Done - Archived | 2 | 2013-07-30 | Details |
| 214 | Esperion Hypercholesterolemia 009 | 1002-009 | Esperion Therapeutics, Inc. | Done - Archived | 2 | 2014-01-29 | Details |
| 258 | Ferrer HTN/Cholesterol 1501 | FCD-PP-1501 | Ferrer Internacional, S.A. | PI Declined | 2b | 2015-12-22 | Details |
| 157 | Forest Hypertension NAC-MD-01 | Forest Research Institute | Done - Archived | 3 | 2012-07-24 | Details | |
| 216 | Forest Hypertension NAC-MD-03 | NAC-MD-03 | Forest Research Institute | Cancelled | 3B | 2014-02-03 | Details |
| 160 | Forest Hypertension NEB-MD-29 | Forest Research Institute | Not Selected | 2012-08-16 | Details | ||
| 105 | Forest MDD 02 | VLZ-MD-02 | Forest Research Institute | Done - Archived | 4 | 2012-03-02 | Details |
| 230 | Forest MDD LVM-MD-15 | LVM-MD-15 | Forest Research Institute | Cancelled | 4 | 2014-10-08 | Details |
| 141 | Forest MDD RGH-MD-75 | Forest Research Institute | Not Selected | 2012-06-22 | Details | ||
| 10 | Forest NEB-MD-04 | NEB-MD-04 | Forest Research Institute | Done - Archived | 3 | 2010-05-21 | Details |
| 11 | Forest NEB-MD-11 | NEB-MD-11 | Forest Research Institute | Done - Archived | 4 | 2010-05-21 | Details |
| 12 | Forest NEB-MD-16 | NEB-MD-16 | Forest Research Institute | Done - Archived | 3 | 2010-05-21 | Details |
| 13 | Forest NEB-MD-19 | Forest Research Institute | Done - Archived | 2010-05-21 | Details | ||
| 14 | Forest NEB-MD-20 | NEB-MD-20 | Forest Research Institute | Done - Archived | 3 | 2010-05-21 | Details |
| 174 | Forest OA-Knee GRT | GRT-MD-101 | Forest Research Institute | Done - Archived | 2b | 2013-01-18 | Details |
| 338 | FORMA NASH 201 | 4101-MET-201 | Forma Therapeutics | Done - Archived | 1/2 | 2019-05-03 | Details |
| 92 | Free Clinic | CRI | Done - Archived | 2011-07-20 | Details | ||
| 469 | Free Clinic-Lonestar | CRI | Done - Archived | 2024-01-22 | Details | ||
| 42 | Free Testing | CRI | Done - Archived | 2010-06-16 | Details | ||
| 284 | Free Testing 2017 | CRI | Done - Archived | 2016-12-16 | Details | ||
| 490 | Gasherbrum Obesity 06 | GSBR-1290-06 | Gasherbrum Bio, Inc. | Follow-up | 2b | 2024-08-13 | Details |
| 496 | Gasherbrum Obesity 09 | GSBR-1290-09 | Gasherbrum Bio, Inc. | Follow-up | 2a | 2024-10-16 | Details |
| 419 | Gilead NASH | Gilead | Not Selected | 2022-05-24 | Details | ||
| 277 | Grunenthal KF7013-03 | KF7013-03 | Grunenthal | Done - Archived | III | 2016-10-17 | Details |
| 311 | Grunenthal KF7013-04 | KF7013-04 | Grunenthal | PI Declined | 3 | 2018-03-13 | Details |
| 49 | Grunenthal Neuropathy KF0151Y/10 | Grunenthal | Done - Archived | 2b | 2010-06-29 | Details | |
| 226 | Grunenthal Pain KF7013-01 | KF7013-01 | Grunenthal | Done - Archived | 2/3 | 2014-09-17 | Details |
| 108 | GSK Chronic Kidney Disease 6581 | GlaxoSmithKline | Done - Archived | 2a | 2012-04-24 | Details | |
| 468 | GSK NASH SKYLINE | 218675 | GlaxoSmithKline | Pending Closeout | 2a | 2023-11-14 | Details |
| 15 | GSK53 Harmony | GLP112753 | GlaxoSmithKline | Done - Archived | 3 | 2010-05-21 | Details |
| 16 | GSK54 Harmony | GLP112754 | GlaxoSmithKline | Done - Archived | 3 | 2010-05-21 | Details |
| 17 | GSK57 Harmony | GLP112757 | GlaxoSmithKline | Done - Archived | 3 | 2010-05-21 | Details |
| 18 | GSK86 Harmony | GLP108486 | GlaxoSmithKline | Done - Archived | 3 | 2010-05-21 | Details |
| 209 | Hanmi DM2 203 | HM-EXC-203 | Hanmi Pharmaceuticals Co. Ltd | Done - Archived | 2 | 2013-09-10 | Details |
| 213 | Hanmi DM2 204 | HM-EXC-204 | Hanmi Pharmaceuticals Co. Ltd | Done - Archived | 2 | 2014-01-29 | Details |
| 328 | Hanmi HM-TRIA-102 | HM-TRIA-102 | Hanmi Pharmaceuticals Co. Ltd | Done - Archived | 1 | 2018-12-06 | Details |
| 450 | Health Screening 2023 | CRI | Enrollment | 2023-05-12 | Details | ||
| 501 | Health Screening-FC 2025 | CRI | Enrollment | 2025-05-22 | Details | ||
| 349 | Health Screening-SB | CRI | Done - Archived | 2019-10-04 | Details | ||
| 424 | Hengurai DM2 | Hengurai | Not Selected | 2022-05-25 | Details | ||
| 436 | Hightide NASH 014 | HTD1801.PCT014 | Hightide Therapeutics | Pending Closeout | 2b | 2022-09-02 | Details |
| 129 | Hoffman LaRoche MDD | Roche | Not Selected | 2012-06-20 | Details | ||
| 415 | ICON Flu A and B | Not Specified | Not Selected | 2022-05-24 | Details | ||
| 307 | Impax Peds Migraine IPX229-B12-01 | IPX229-B16-01 | Impax Laboratories, Inc | PI Declined | 3 | 2017-12-22 | Details |
| 240 | Innocoll Diabetic Foot Ulcer INN-TOP-004 | INN-TOP-004 | Innocoll Pharmaceuticals | Done - Archived | 3 | 2015-05-06 | Details |
| 414 | Innovent CIBI 314A201-256338 Covid | Innovent | Not Selected | 2022-05-24 | Details | ||
| 19 | Intarcia Diabetes 02 | Intarcia Therapeutics, Inc. | Done - Archived | 2 | 2010-05-21 | Details | |
| 189 | Intarcia DM2 105 | ITCA 650-CLP-105 | Intarcia Therapeutics, Inc. | Done - Archived | 3 | 2013-08-15 | Details |
| 181 | Intarcia DM2 107 | ITCA 650-CLP-107 | Intarcia Therapeutics, Inc. | Done - Archived | 3/4 | 2013-07-23 | Details |
| 290 | Intarcia ITCA 650-CLP-203 | ITCA 650-CLP-203 | Intarcia Therapeutics, Inc. | Done - Archived | 3b | 2017-03-14 | Details |
| 485 | Intra-Cellular Bipolar 451 | ITI-007-451 | Intra-Cellular Therapies | Follow-up | 3 | 2024-05-24 | Details |
| 388 | Intra-Cellular Therapies Schizophrenia 304 | ITI-007-304 | Intra-Cellular Therapies | Done - Archived | 3 | 2021-05-05 | Details |
| 379 | Ionis HTN ISIS 757456-CS4 | ISIS 757456-CS4 | Ionis Pharmaceuticals | Done - Archived | 2 | 2021-01-25 | Details |
| 403 | Ionis Hypertriglyceridemia CS8 | ISIS 678354-CS8 | Ionis Pharmaceuticals | Done - Archived | 2b | 2022-03-23 | Details |
| 178 | ISIS Diabetes 449884-CS2 | ISIS 449884-CS2 | ISIS Pharmaceuticals | Done - Archived | 2 | 2013-05-21 | Details |
| 244 | ISIS DM2 449884-CS4 | 449884-CS4 | ISIS Pharmaceuticals | Done - Archived | 2 | 2015-06-02 | Details |
| 334 | JandJ MDD K76-US10049 | K76-US10049 | Johnson & Johnson Pharmaceuticals | Not Selected | 2019-03-13 | Details | |
| 272 | Janssen MDD 2001 | 42847922MDD2001 | Janssen | Done - Archived | 2b | 2016-08-10 | Details |
| 361 | Janssen MDD 3001 | 42847922MDD3001 | Janssen | Done - Archived | 3 | 2020-06-03 | Details |
| 375 | Janssen Vaccine VAC31518COV3009 | VAC31518COV3009 | Janssen | PI Declined | 3 | 2020-10-23 | Details |
| 354 | Jazz MDD | JZP188-301 | Jazz Pharmaceuticals | Cancelled | 2019-12-18 | Details | |
| 473 | Jina Bipolar 72189812 | 72189812 | Jina Pharmaceuticals | PI Declined | 3 | 2024-02-21 | Details |
| 196 | JNJ DPN 42160443 | JNJ-42160443 | Johnson & Johnson Pharmaceuticals | Not Selected | 2013-09-10 | Details | |
| 20 | Johnson and Johnson Diabetes 3002 | 28431754DIA3002 | Johnson & Johnson Pharmaceuticals | Done - Archived | 3 | 2010-05-21 | Details |
| 369 | Karuna KAR-007 | KAR-007 | Karuna Therapeutics | Done - Archived | 3 | 2020-09-08 | Details |
| 370 | Karuna KAR-008 | KAR-008 | Karuna Therapeutics | Done - Archived | 2020-09-08 | Details | |
| 279 | Kowa K-877-301 | K-877-301 | Kowa Research Institute, Inc. | Done - Archived | 3 | 2016-10-26 | Details |
| 285 | Kowa K-877-302 | Kowa Research Institute, Inc. | Not Selected | 2017-01-05 | Details | ||
| 278 | Kowa K-877-303 | K-877-303 | Kowa Research Institute, Inc. | Done - Archived | 3 | 2016-10-26 | Details |
| 250 | Kowa Lipids NK-104-CR-3.01US | NK-104-CR-3.01US | Kowa Research Institute, Inc. | Done - Archived | 3 | 2015-09-03 | Details |
| 249 | Kowa Lipids NK-104-CR-3.03US Ext | NK-104-CR-3.03US | Kowa Research Institute, Inc. | Cancelled | 3 | 2015-09-03 | Details |
| 398 | KOWA NASH 201 | K-001-201 | Kowa Research Institute, Inc. | PI Declined | 2 | 2022-01-11 | Details |
| 269 | Ligand DM2 6972 | L6972-04 | Ligand Pharmaceuticals | Done - Archived | 2 | 2016-07-27 | Details |
| 484 | Lilly Alzheimers HBEO | I7S-MC-HBEO | Eli Lilly and Company | PI Declined | 2 | 2024-05-24 | Details |
| 405 | Lilly BDCY DM1 | I8H-MC-BDCY | Eli Lilly and Company | Done - Archived | 3 | 2022-04-11 | Details |
| 362 | Lilly COVID PYAB | J2W-MC-PYAB | Eli Lilly and Company | Done - Archived | 2 | 2020-07-20 | Details |
| 207 | Lilly DM 1-Insulin | NCGS Inc | Cancelled | 2013-09-10 | Details | ||
| 404 | Lilly DM 2 BDCX | I8H-MC-BDCX | Eli Lilly and Company | Done - Archived | 3 | 2022-03-25 | Details |
| 365 | Lilly DM BDCL | I8H-MC-BDCL | Eli Lilly and Company | PI Declined | 2 | 2020-08-20 | Details |
| 310 | Lilly DM GBGL | H9X-MC-GBGL | Eli Lilly and Company | Done - Archived | 3 | 2018-02-20 | Details |
| 100 | Lilly DM2 BIAM | Eli Lilly and Company | Done - Archived | 3 | 2011-11-07 | Details | |
| 275 | Lilly DM2 GBGJ | H9X-MC-GBGJ | Eli Lilly and Company | Done - Archived | 2 | 2016-10-06 | Details |
| 289 | Lilly DM2 GPGB | I8F-MC-GPGB | Eli Lilly and Company | Done - Archived | 2 | 2017-02-27 | Details |
| 296 | Lilly DM2 GPGF | I8F-MC-GPGF | Eli Lilly and Company | Done - Archived | 2 | 2017-08-07 | Details |
| 322 | Lilly DM2 GPGH | I8F-MC-GPGH | Eli Lilly and Company | Done - Archived | 3 | 2018-08-13 | Details |
| 330 | Lilly DM2 GPGK | I8F-MC-GPGK | Eli Lilly and Company | Done - Archived | 2019-02-19 | Details | |
| 339 | Lilly DM2 GPGL | I8F-MC-GPGL | Eli Lilly and Company | Done - Archived | 3 | 2019-05-07 | Details |
| 407 | Lilly DM2 GPHE | I8F-MC-GPHE | Eli Lilly and Company | Done - Archived | 4 | 2022-05-02 | Details |
| 324 | Lilly DM2-Cardiac GPGM | I8F-MC-GPGM | Eli Lilly and Company | Done - Archived | 3 | 2018-08-29 | Details |
| 122 | Lilly GBDE | H9X-MC-GBDE | Eli Lilly and Company | Done - Archived | 3b | 2012-05-15 | Details |
| 155 | Lilly GBDG | H9X-MC-GBDG | Eli Lilly and Company | Done - Archived | 3b | 2012-07-19 | Details |
| 347 | Lilly GPHK Obesity DM-2 | I8F-MC-GPHK | Eli Lilly and Company | Done - Archived | 3 | 2019-10-02 | Details |
| 341 | Lilly GPHR NASH | I8F-MC-GPHR | Eli Lilly and Company | Done - Archived | 2 | 2019-06-24 | Details |
| 383 | Lilly GZBD | J1I-MC-GZBD | Eli Lilly and Company | Done - Archived | 2 | 2021-04-01 | Details |
| 452 | Lilly GZBU | J1L-MC-GZBU | Eli Lilly and Company | Pending Closeout | 2b | 2023-05-30 | Details |
| 445 | Lilly GZGP | J2A-MC-GZGP | Eli Lilly and Company | Follow-up | 3 | 2023-03-17 | Details |
| 154 | Lilly H9X-MC-GBDH | Eli Lilly and Company | Not Selected | 2012-07-19 | Details | ||
| 156 | Lilly I5E-MC-TSAT | Eli Lilly and Company | Not Selected | 2012-07-19 | Details | ||
| 380 | Lilly I8F-MC-GPHL | I8F-MC-GPHL | Eli Lilly and Company | Done - Archived | 3 | 2021-01-25 | Details |
| 67 | Lilly MDD H9P-MC-LNBR | H9P-MC-LNBR | Eli Lilly and Company | Done - Archived | 3 | 2010-12-10 | Details |
| 161 | Lilly MDD LNBQ | H9P-MC-LNBQ | Eli Lilly and Company | Done - Archived | 3 | 2012-08-30 | Details |
| 254 | Lilly Migraine CGAH | I5Q-MC-CGAH | Eli Lilly and Company | Done - Archived | 3 | 2015-09-28 | Details |
| 381 | Lilly Obesity GPHM | I8F-MC-GPHM | Eli Lilly and Company | Done - Archived | 3 | 2021-01-29 | Details |
| 442 | Lilly Obesity-DM2 GZGQ | J2A-MC-GZGQ | Eli Lilly and Company | Pending Closeout | 3 | 2023-02-13 | Details |
| 312 | Lilly UC I6T-MC-AMAN | I6T-MC-AMAN | Eli Lilly and Company | Done - Archived | 3 | 2018-03-30 | Details |
| 313 | Lilly UC I6T-MC-AMBG | I6T-MC-AMBG | Eli Lilly and Company | Done - Archived | 3 | 2018-03-30 | Details |
| 168 | Lundbeck MDD | Lundbeck | Not Selected | 2012-10-22 | Details | ||
| 351 | Madrigal NAFLD MGL-3196-14 | MGL-3196-14 | Madrigal Pharmaceuticals | Done - Archived | 3 | 2019-11-20 | Details |
| 396 | Madrigal NAFLD MGL-3196-18 | Madrigal Pharmaceuticals | PI Declined | 2021-09-16 | Details | ||
| 98 | Mallinckrodt/Covidien OA 0181 | COV15000181US | Mallinckrodt Inc. | Done - Archived | 3 | 2011-10-10 | Details |
| 21 | MAP Migraine 301 | MAP0004-Cl-P301 | MAP Pharmaceuticals, Inc. | Done - Archived | 3 | 2010-05-21 | Details |
| 75 | Masimo Non-invasive Parameter Testing with Pulse CO-Oximetry | TP-15917 | Masimo Corporation | Done - Archived | 2011-03-03 | Details | |
| 303 | Medimmune Coronary Heart Disease | D7870C00002 | MedImmune | Not Selected | 2a | 2017-10-19 | Details |
| 104 | Merck Bipolar 1 P06384 | Merck Inc. | Done - Archived | 3b | 2012-01-23 | Details | |
| 22 | Merck Diabetes 102 | 102:MK-0431C | Merck Inc. | Done - Archived | 3 | 2010-05-21 | Details |
| 60 | Merck Diabetes 180 | Merck Inc. | Cancelled | 2010-08-05 | Details | ||
| 179 | Merck DM 027 | MK-3102-027-00 | Merck Inc. | Done - Archived | 3 | 2013-06-21 | Details |
| 212 | Merck DM MK-8835-002 | MK-8835-002 | Merck Inc. | Done - Archived | 3 | 2014-01-20 | Details |
| 219 | Merck DM MK-8835-005-00 | MK-8835-005-00 | Merck Inc. | Done - Archived | 3 | 2014-02-28 | Details |
| 101 | Merck DM2 260 | 0431-260-00 | Merck Inc. | Done - Archived | 3 | 2011-11-07 | Details |
| 220 | Merck DM2 MK-8835-006-00 | MK-8835-006-00 | Merck Inc. | Done - Archived | 3 | 2014-04-09 | Details |
| 43 | Merck Migraine 065 | MK-0974-065-00 | Merck Inc. | Done - Archived | 2/3 | 2010-06-18 | Details |
| 158 | Merck MK-0431D-266 | Merck Inc. | Done - Archived | 3 | 2012-08-01 | Details | |
| 382 | Merck NAFLD 6024-001 | MK-6024-001-00 | Merck Inc. | Done - Archived | 2a | 2021-04-01 | Details |
| 364 | Merck NASH MK3655-001 | MK3655-001 | Merck Inc. | Done - Archived | 2b | 2020-08-10 | Details |
| 417 | Merck Vaccine V116 | V116-005-0067 | Merck Inc. | Done - Archived | 3 | 2022-05-24 | Details |
| 373 | Merck Vaccine V590-003 | V590-003 | Merck Inc. | Cancelled | 2020-10-07 | Details | |
| 68 | Metabolic Solutions DM 2 C004 | MSDC-C004 | Metabolic Solutions | Done - Archived | 2B | 2011-01-03 | Details |
| 376 | Metacrine MET409-201 | MET409-201 | Metacrine, Inc. | Done - Archived | 2 | 2020-10-28 | Details |
| 421 | Mineralys HTN 202 | MLS-101-202 | Mineralys Therapeutics | Done - Archived | 2 | 2022-05-24 | Details |
| 420 | Mineralys HTN/Obesity/Obstructive Sleep Apnea | MLS-101-203 | Mineralys Therapeutics | Not Selected | 2 | 2022-05-24 | Details |
| 440 | Moderna Vaccine mRNA-1647-P301 | mRNA-1647-P301 | ModernaTX, Inc. | Follow-up | 3 | 2023-01-20 | Details |
| 304 | Mylan DM 1 3004 | MYL-1501D-3004 | Mylan | Done - Archived | 3 | 2017-10-20 | Details |
| 451 | Nail Genesis Toe Fungus 02 | CT002-02 | Nail Genesis LLC | On Hold | 2023-05-23 | Details | |
| 453 | Nail Genesis Toe Fungus-Metro | CT1002-02 | Nail Genesis LLC | On Hold | 2023-06-08 | Details | |
| 197 | NCGS Migraine | NCGS Inc | Not Selected | 2013-09-10 | Details | ||
| 456 | NeuroBo NASH DA1241_NASH_IIa | DA1241_NASH_IIa | NeuroBo Pharmaceuticals, Inc | Done - Archived | 2a | 2023-07-17 | Details |
| 199 | Novartis Migraine 863-P303 | 863-P-303 | Novartis | Cancelled | 3 | 2013-09-10 | Details |
| 386 | Novartis NAFLD 2001 | CADPT02A2001 | Novartis | Cancelled | 2021-04-26 | Details | |
| 348 | Novartis NASH LJN452D2201C | LJN452D2201C | Novartis | PI Declined | 2B | 2019-10-04 | Details |
| 138 | Novartis Schizophrenia | Novartis | Not Selected | 2012-06-21 | Details | ||
| 374 | Noven OA Knee HP-5000-US-07 | HP-5000-US-07 | Noven | PI Declined | 3 | 2020-10-13 | Details |
| 315 | NovMeta Pharma DM 002 | NMP-CYZ-P2-002 | NovMeta Pharma Co., Ltd. | Done - Archived | 2 | 2018-04-25 | Details |
| 321 | Novo 4388 | Novo Nordisk | PI Declined | 2018-08-08 | Details | ||
| 23 | Novo Diabetes 3672 | NN1250-3672 | Novo Nordisk | Done - Archived | 3a | 2010-05-21 | Details |
| 24 | Novo Diabetes 3839 | NN1250-3839 | Novo Nordisk | Done - Archived | 3a | 2010-05-21 | Details |
| 25 | Novo Lira1842 | NN2211-1842 | Novo Nordisk | Done - Archived | 3b | 2010-05-21 | Details |
| 26 | Novo Lira1923 | Novo Nordisk | Done - Archived | 3a | 2010-05-21 | Details | |
| 80 | Novo Nordisk BEGIN NN1250-3923 | Novo Nordisk | Done - Archived | 3b | 2011-04-06 | Details | |
| 74 | Novo Nordisk Diabetes DUAL 3697 | NN9068-3697 | Novo Nordisk | Done - Archived | 3b | 2011-02-28 | Details |
| 221 | Novo Nordisk DM 1 ADJUNCT 4083 | NN9211-4083 | Novo Nordisk | Done - Archived | 3A | 2014-04-11 | Details |
| 180 | Novo Nordisk DM 3851 | NN9068-3851 | Novo Nordisk | Done - Archived | 2013-07-17 | Details | |
| 191 | Novo Nordisk DM SWITCH 2 3998 | NN1250-3998 | Novo Nordisk | Done - Archived | 3b | 2013-09-10 | Details |
| 77 | Novo Nordisk DM2 BOOST 3844 | NN5401-3844 | Novo Nordisk | Done - Archived | 3b | 2011-03-25 | Details |
| 188 | Novo Nordisk DM2 DEVOTE 4080 | EX1250-4080 | Novo Nordisk | Done - Archived | 3b | 2013-08-02 | Details |
| 202 | Novo Nordisk DM2 NN9535-3624 | NN9535-3624 | Novo Nordisk | Not Selected | 2013-09-10 | Details | |
| 232 | Novo Nordisk DUAL II 4185 | NN9068-4185 | Novo Nordisk | Done - Archived | 3b | 2015-03-04 | Details |
| 56 | Novo Nordisk LEADER 3748 | EX2211-3748 | Novo Nordisk | Done - Archived | 3b | 2010-08-03 | Details |
| 51 | Novo Nordisk Levemir Diet 3785 | NN304-3785 | Novo Nordisk | Done - Archived | 4 | 2010-06-29 | Details |
| 253 | Novo Nordisk NN2211-4232 | NN2211-4232 | Novo Nordisk | Done - Archived | 4 | 2015-09-25 | Details |
| 252 | Novo Nordisk NN9535-4216 | NN9535-4216 | Novo Nordisk | Done - Archived | 3b | 2015-09-18 | Details |
| 461 | Novo Nordisk NN9541-4945 | NN9541-4945 | Novo Nordisk | Follow-up | 2 | 2023-09-25 | Details |
| 266 | Novo Nordisk Pioneer 4233 | NN9924-4233 | Novo Nordisk | Done - Archived | 3a | 2016-07-25 | Details |
| 282 | Novo Nordisk SUSTAIN 8 NN9535-4270 | NN9535-4270 | Novo Nordisk | Done - Archived | 3b | 2016-12-08 | Details |
| 291 | Novo Nordisk SUSTAIN 9 NN9535-4269 | NN9535-4269 | Novo Nordisk | PI Declined | 2017-05-03 | Details | |
| 131 | Novo-Nordisk 3944 | Novo Nordisk | Not Selected | 2012-06-21 | Details | ||
| 204 | Novo-Nordisk SUSTAIN 3623 | NN9535-3623 | Novo Nordisk | Done - Archived | 3a | 2013-09-10 | Details |
| 222 | NuSirt Biopharma DM2 NS-0100-01 | NS-0100-01 | NuSirt BioPharma | Done - Archived | 2A | 2014-06-27 | Details |
| 223 | NuSirt Biopharma DM2 NS-0100-01E | NS-0100-01E | NuSirt BioPharma | Done - Archived | 2A | 2014-06-27 | Details |
| 243 | NuSirt NS-200 | NS-200 | NuSirt BioPharma | Done - Archived | 2a | 2015-05-15 | Details |
| 301 | NuSirt Obesity NS-WM-01 | NS-WM-01 | NuSirt BioPharma | Done - Archived | 2 | 2017-10-05 | Details |
| 268 | OPC Pain 2065-5 | 2065-5 | Opioid PMR Consortium | Done - Archived | 4 | 2016-07-25 | Details |
| 372 | Oramed DM/NASH N02 | ORA-D-N02 | Oramed Pharmaceuticals | Done - Archived | 2 | 2020-10-07 | Details |
| 422 | Oramed DM2 | Oramed Pharmaceuticals | Not Selected | 2022-05-25 | Details | ||
| 363 | Oramed DM2 ORA-D-013-1 | ORA-D-013-1 | Oramed Pharmaceuticals | Done - Archived | 3 | 2020-07-27 | Details |
| 309 | Oramed DM2 ORA-D-015 | ORA-D-015 | Oramed Pharmaceuticals | Done - Archived | 2b | 2018-02-08 | Details |
| 389 | Oramed ORA-D-013-1 SB | ORA-D-013-1 | Oramed Pharmaceuticals | Done - Archived | 3 | 2021-05-10 | Details |
| 371 | Oramed ORA-D-013-2 | ORA-D-013-2 | Oramed Pharmaceuticals | Done - Archived | 3 | 2020-09-10 | Details |
| 111 | Ortho-McNeil Schizophrenia 4005 | Ortho-McNeil | Done - Archived | 3B | 2012-05-03 | Details | |
| 190 | Osteoarthtitis Knee | Not Specified | Not Selected | 2 | 2013-09-09 | Details | |
| 166 | Otsuka Bipolar 252 | Otsuka Pharmaceuticals | Done - Archived | 3 | 2012-10-11 | Details | |
| 331 | Otsuka 331-201-00079 | 331-201-00079 | Otsuka Pharmaceuticals | PI Declined | 3 | 2019-02-22 | Details |
| 66 | Otsuka Adolescent Schizophrenia 266 | Otsuka Pharmaceuticals | PI Declined | 4 | 2010-10-29 | Details | |
| 33 | Otsuka Adolescent Schizophrenia 267 | Otsuka Pharmaceuticals | PI Declined | 4 | 2010-05-21 | Details | |
| 152 | Otsuka Bipolar I 250 | Otsuka Pharmaceuticals | Done - Archived | 3 | 2012-06-29 | Details | |
| 93 | Otsuka MDD 228 | Otsuka Pharmaceuticals | PI Declined | 2011-08-08 | Details | ||
| 57 | Otsuka MDD 257 EXT | 31-08-257 | Otsuka Pharmaceuticals | Done - Archived | 3 | 2010-08-03 | Details |
| 55 | Otsuka MDD 263 | 31-08-263 | Otsuka Pharmaceuticals | Done - Archived | 3 | 2010-08-02 | Details |
| 171 | Otsuka MDD 282 | 331-12-282 | Otsuka Pharmaceuticals | PI Declined | 3 | 2012-10-30 | Details |
| 195 | Otsuka MDD 331-13-001 | 331-13-001 | Otsuka Pharmaceuticals | Cancelled | 3b | 2013-09-10 | Details |
| 350 | Otsuka PTSD 331-201-00071 | 331-201-00071 | Otsuka Pharmaceuticals | Done - Archived | 3 | 2019-11-19 | Details |
| 27 | Otsuka Schizophrenia 248 | 31-08-248 | Otsuka Pharmaceuticals | Done - Archived | 3 | 2010-05-21 | Details |
| 182 | Palm Beach Research Natural Cold | Palm Beach Research | Cancelled | 2013-07-23 | Details | ||
| 431 | Parexel Asthma 113844 4D | Parexel | Not Selected | 1/2 | 2022-06-01 | Details | |
| 430 | Parexel Asthma 217654 | Parexel | Not Selected | 3 | 2022-06-01 | Details | |
| 320 | PegBio DM2 PB119202 | PB119202 | PegBio Co., LTD | Done - Archived | 2 | 2018-08-06 | Details |
| 428 | Perception Neuroscience MDD | PCN-101-21 | Perception Neuroscience, Inc | Not Selected | 2022-05-26 | Details | |
| 203 | Pfizer CLBP A4091059 | A4091059 | Pfizer | Not Selected | 3 | 2013-09-10 | Details |
| 336 | Pfizer DM 2 C3421005 | C3421005 | Pfizer | Done - Archived | 2b | 2019-04-10 | Details |
| 358 | Pfizer DM2 C3421008 | C3421008 | Pfizer | Done - Archived | 2A | 2020-03-02 | Details |
| 217 | Pfizer DMD2 | B1731006 | Pfizer | Not Selected | 2A | 2014-02-03 | Details |
| 206 | Pfizer DNP B3291014 | B3291014 | Pfizer | Not Selected | 2 | 2013-09-10 | Details |
| 446 | Pfizer Hepatic Impairment C5091014 | C5091014 | Pfizer | Done - Archived | 1 | 2023-05-03 | Details |
| 241 | Pfizer Low Back Pain A4091059 | A4091059 | Pfizer | Done - Archived | 3 | 2015-05-15 | Details |
| 28 | Pfizer MDD 4437 | 3151A12-4437-US | Pfizer | Done - Archived | 4 | 2010-05-21 | Details |
| 47 | Pfizer MDD DVS-3364 | 3151A1-3364-US | Pfizer | Done - Archived | 4 | 2010-06-28 | Details |
| 327 | Pfizer NAFLD C3711001 | C3711001 | Pfizer | Done - Archived | 2a | 2018-11-12 | Details |
| 368 | Pfizer NASH C3711005 | C3711005 | Pfizer | Done - Archived | 2A | 2020-09-02 | Details |
| 425 | Pfizer Nash C3711005 Part 2 | C3711005 | Pfizer | Not Selected | 2022-05-26 | Details | |
| 238 | Pfizer OA-Hip/Knee A4091058 | A4091058 | Pfizer | Done - Archived | 3 | 2015-04-20 | Details |
| 239 | Pfizer OA-Hip/Knee Sub-Study A4091064 | A4091064 | Pfizer | PI Declined | 3 | 2015-04-20 | Details |
| 399 | Pfizer OA-Knee 003 | Pfizer | Cancelled | 2022-02-24 | Details | ||
| 435 | Pfizer Obesity-DM2 C3991004 | C3991004 | Pfizer | Done - Archived | 2 | 2022-09-02 | Details |
| 201 | Pfizer/Inventiv OA of Hip/Knee A4091056 | A4091056 | Pfizer | Not Selected | 3 | 2013-09-10 | Details |
| 192 | Pfizert/i3 CLBP | PharmaNet | Not Selected | 2013-09-10 | Details | ||
| 151 | Pharm Olam Over Active Bladder | Pharm Olam | Not Selected | 2012-06-28 | Details | ||
| 65 | Pozen Gastric Ulcers 302 | PA32540-302 | Pozen | Done - Archived | 3 | 2010-10-29 | Details |
| 427 | PPD DM2 | Blue Star Genomics | Not Selected | 2022-05-26 | Details | ||
| 200 | PRA DM2 | Unknown | Cancelled | 2013-09-10 | Details | ||
| 110 | Proctor and Gamble Constipation | Procter & Gamble | Done - Archived | 2 | 2012-05-03 | Details | |
| 237 | Proteus Device PB-DISC_CMB-01 | PB-DISC_CMB-01 | Proteus Digital Health, Inc | Done - Archived | Device (Arm 1) | 2015-04-01 | Details |
| 130 | Purdue Back Pain Study | Purdue Pharma LP | Not Selected | 2012-06-21 | Details | ||
| 29 | Purdue BUP3025 | BUP3025 | Purdue Pharma LP | Done - Archived | 3 | 2010-05-21 | Details |
| 96 | Purdue CLBP - Controlled 3705 | ONU3705 | Purdue Pharma LP | Done - Archived | 3 | 2011-10-10 | Details |
| 97 | Purdue CLBP - Uncontrolled 3704 | ONU3704 | Purdue Pharma LP | Done - Archived | 3 | 2011-10-10 | Details |
| 88 | Purdue Pharma CLBP ONU3701 | Purdue Pharma LP | Done - Archived | 3 | 2011-04-06 | Details | |
| 70 | Reata CKD 0903 | Reata Pharmaceuticals | Cancelled | 2011-01-12 | Details | ||
| 340 | Recruitment | CRI | Done - Archived | 2019-06-11 | Details | ||
| 194 | Redhill H. pylori RHB-105-01 | RHB-105-01 | Redhill Biopharma Ltd | Done - Archived | 3 | 2013-09-10 | Details |
| 234 | Redhill H.Pylori-Central Location | Redhill Biopharma Ltd | Cancelled | 3 | 2015-03-18 | Details | |
| 463 | Referral Program | CRI | Enrollment | 2023-10-04 | Details | ||
| 457 | Regeneron R17092-COV-2313 | R17092-COV-2313 | Regeneron Pharmaceuticals, Inc. | Cancelled | 3 | 2023-08-29 | Details |
| 366 | Regeneron COVID-19 2067 | R10933-10987-COV-2067 | Regeneron Pharmaceuticals, Inc. | Done - Archived | Adaptive 1/2/3 | 2020-08-26 | Details |
| 367 | Regeneron COVID-19 2069 | R10933-10987-COV-2069 | Regeneron Pharmaceuticals, Inc. | Done - Archived | 3 | 2020-08-26 | Details |
| 300 | Regeneron OA Knee/Hip R475-OA-1688 | R475-OA-1688 | Regeneron Pharmaceuticals, Inc. | Done - Archived | 3 | 2017-09-08 | Details |
| 499 | Regor Obseity RGT001-075-205 | RGT001-075-205 | Regor Pharmaceuticals | Cancelled | 2 | 2025-01-09 | Details |
| 116 | Repros Low Testosterone ZA-300 | Repros Therapeutics Inc. | Done - Archived | 3 | 2012-05-07 | Details | |
| 119 | Repros Low Testosterone ZA-301 | Repros Therapeutics Inc. | PI Declined | 3 | 2012-05-08 | Details | |
| 480 | Reviva Schizophrenia RVP-30-002 | RVP-30-002 | Reviva Pharmaceuticals | Cancelled | 3 | 2024-04-19 | Details |
| 259 | Ritter Pharmaceuticals Lactose Intolerance | G28-003 | Ritter Pharmaceuticals | Done - Archived | 2b/3 | 2016-01-11 | Details |
| 454 | Rivus RIV-HU6-2202 | RIV-HU6-2202 | Rivus Pharmaceuticals | Pending Closeout | 2 | 2023-06-13 | Details |
| 471 | RivusRIV-Hu6-2202Metro | RIV-Hu6-2202 | Rivus Pharmaceuticals | Done - Archived | 2 | 2024-01-24 | Details |
| 162 | Roche Diabetes 025 | Roche | Done - Archived | 3 | 2012-09-06 | Details | |
| 170 | Roche Diabetes 034 | Roche | Done - Archived | 3 | 2012-10-30 | Details | |
| 133 | Roche Diabetes 035 | Roche | Done - Archived | 3 | 2012-06-21 | Details | |
| 172 | Roche Diabetic Rentiopathy | Roche | Not Selected | 2012-10-31 | Details | ||
| 233 | Roche DM2 BP29476 | BP29476 | Roche | Done - Archived | 2A | 2015-03-17 | Details |
| 30 | Roche EMERGE | BC21893B | Roche | Done - Archived | 3 | 2010-05-21 | Details |
| 323 | Roche Schizophrenia BP40283 Part A | BP40283 | Roche | Done - Archived | 2 | 2018-08-21 | Details |
| 352 | Roche Schizophrenia BP40283 Part B | BP40283 Part B | Roche | Done - Archived | 2 | 2019-12-09 | Details |
| 385 | Sagimet NASH 005 EXT | 3V2640-CLIN-005 | Sagimet Biosciences | Done - Archived | 2 | 2021-04-21 | Details |
| 384 | Sagimet SB2640-CLIN-007 | SB2640-CLIN-007 | Sagimet Biosciences | Done - Archived | 2B | 2021-04-16 | Details |
| 41 | Sangamo Neuropathy 0901 | SB-509-0901 | Sangamo BioSciences, Inc | Done - Archived | 2B | 2010-06-01 | Details |
| 58 | Sanofi Aventis 6911 | EFC6911 | Sanofi-Aventis | Done - Archived | 3 | 2010-08-03 | Details |
| 59 | Sanofi Aventis Schizophrenia 6726 | DRI6726 | Sanofi-Aventis | Done - Archived | 3 | 2010-08-03 | Details |
| 115 | Sanofi Aventis Urinary Incontinence 6271 | Sanofi-Aventis | Done - Archived | 2012-05-04 | Details | ||
| 198 | Sanofi DM EFC12404 | EFC12404 | Sanofi-Aventis | Done - Archived | 3 | 2013-09-10 | Details |
| 211 | Sanofi DM EFC12405 | EFC12405 | Sanofi-Aventis | Done - Archived | 3 | 2014-01-10 | Details |
| 274 | Sanofi EFC14833 | EFC14833 | Sanofi-Aventis | Done - Archived | 3 | 2016-09-20 | Details |
| 287 | Sanofi EFC14835 | EFC14835 | Sanofi-Aventis | Done - Archived | 3 | 2017-01-20 | Details |
| 294 | Sanofi EFC14838 | EFC14838 | Sanofi-Aventis | Cancelled | 3 | 2017-07-14 | Details |
| 297 | Sanofi EFC14867 | EFC14867 | Sanofi-Aventis | Cancelled | 3 | 2017-08-11 | Details |
| 292 | Sanofi EFC14868 | ECF14868 | Sanofi-Aventis | Cancelled | 3 | 2017-06-01 | Details |
| 126 | Sanofi Hypercholestrolemia 1569 | EFC11569 | Sanofi-Aventis | Done - Archived | 3 | 2012-06-01 | Details |
| 236 | Sanofi LPS14347 | LPS14347 | Sanofi-Aventis | Not Selected | 2015-04-01 | Details | |
| 264 | Sanofi LPS14584 | LPS14584 | Sanofi-Aventis | Done - Archived | 4 | 2016-03-30 | Details |
| 306 | Sanofi Pasteur Vaccine MET42 | MET42 | Sanofi Pasteur, Inc. | Done - Archived | 3 | 2017-12-18 | Details |
| 32 | Sanofi-Aventis 6016 | EFC6016 | Sanofi-Aventis | Done - Archived | 2010-05-21 | Details | |
| 31 | Sanofi-Aventis 6017 | EFC6017 | Sanofi-Aventis | Done - Archived | 3 | 2010-05-21 | Details |
| 208 | Schizophrenia | Unknown | Not Selected | 2013-09-10 | Details | ||
| 286 | Shionogi Influenza 1601T0831-Healthy | 1601T0831 | Shionogi | Done - Archived | 3 | 2017-01-10 | Details |
| 281 | Shionogi Influenza 1602T0832-High Risk | 1602T0832 | Shionogi | Done - Archived | 3 | 2016-11-18 | Details |
| 448 | Shionogi Obesity 2201N1121 | 2201N1121 | Shionogi | Done - Archived | 2 | 2023-05-10 | Details |
| 128 | Shire MDD 209 | Shire Development, Inc. | Done - Archived | 2 | 2012-06-18 | Details | |
| 164 | Shire MDD Extension 329 | Shire Development, Inc. | Done - Archived | 3 | 2012-09-28 | Details | |
| 139 | Shire Schizophrenia | Shire Development, Inc. | Not Selected | 2012-06-21 | Details | ||
| 173 | Shire Schizophrenia 335 | Shire Development, Inc. | Cancelled | 3 | 2013-01-08 | Details | |
| 175 | Shire Schizophrenia 336 | SPD489-336 | Shire Development, Inc. | Cancelled | 3 | 2013-02-22 | Details |
| 298 | Study XXXXX | Sponsor Name | Cancelled | 2 | 2017-08-14 | Details | |
| 46 | Sunovian Bipolar I Depression 0235 | D1050235 | Sunovion Pharmaceuticals Inc. | Done - Archived | 2010-06-24 | Details | |
| 44 | Sunovian Bipolar I Depression 0256 EXT | D1050256 | Sunovion Pharmaceuticals Inc. | Done - Archived | 3 | 2010-06-23 | Details |
| 402 | Sunovion Phase 1 Schizophrenia (4 trials) | Sunovion Pharmaceuticals Inc. | Not Selected | 2022-02-24 | Details | ||
| 432 | Sunovion SEP361-123 | SEP361-123 | Sunovion Pharmaceuticals Inc. | Done - Archived | 1 | 2022-08-01 | Details |
| 337 | Sunovion SEP361-301 | SEP361-301 | Sunovion Pharmaceuticals Inc. | Done - Archived | 2 | 2019-04-17 | Details |
| 343 | Sunovion SEP361-303 | SEP361-303 | Sunovion Pharmaceuticals Inc. | Done - Archived | 2019-08-19 | Details | |
| 260 | Synergy IBS-C SP304203-05 | SP304203-05 | Synergy Pharmaceuticals | Done - Archived | 3 | 2016-01-27 | Details |
| 149 | Takeda Bipolar TAK-375SL | Takeda | Not Selected | 2012-06-22 | Details | ||
| 118 | Takeda DM2 006 | Takeda | Done - Archived | 2 | 2012-05-07 | Details | |
| 54 | Takeda MDD 314 EXT | Lu AA21004_314 | Takeda | Done - Archived | 3 | 2010-08-02 | Details |
| 45 | Takeda MDD 315 | LuAA21004_315 | Takeda | Done - Archived | 3 | 2010-06-23 | Details |
| 91 | Takeda MDD 318 | Lu AA21004_318 | Takeda | Done - Archived | 3b | 2011-06-13 | Details |
| 251 | Takeda NaltrexBuprop4001 | NaltrexBuprop-4001 | Takeda | Cancelled | 4 | 2015-09-08 | Details |
| 433 | TERNCB-2002 NASH | TERNCB-2002 | Terns Inc | Done - Archived | 2a | 2022-08-11 | Details |
| 359 | Terns NASH 2001 | Tern101-2001 | Terns Inc | Done - Archived | 2a | 2020-03-17 | Details |
| 459 | Teva Schiz TEVA TV-44749-CNS-30096 | TEVA TV-44749-CNS-30096 | TEVA Pharmaceuticals | Cancelled | 3 | 2023-09-15 | Details |
| 423 | TEVA Schizophrenia | TEVA Pharmaceuticals | Not Selected | 2022-05-25 | Details | ||
| 308 | TEVA Schizophrenia 30072 | TV46000-CNS-30072 | TEVA Pharmaceuticals | Done - Archived | 2018-01-22 | Details | |
| 355 | TEVA Schizophrenia 30078 | TV46000-CNS-30078 | TEVA Pharmaceuticals | Done - Archived | 2019-12-18 | Details | |
| 256 | Theracos DM/NAIVE C-449 | THR-1442-C-449 | Theracos Sub, LLC | Done - Archived | 2b | 2015-11-19 | Details |
| 263 | Theracos DM2 C-450 | THR-1442-C-450 | Theracos Sub, LLC | Done - Archived | 3 | 2016-02-10 | Details |
| 247 | Theracos DM2/Cardiac C-476 | THR-1442-C-476 | Theracos Sub, LLC | Done - Archived | 3 | 2015-09-01 | Details |
| 265 | Theracos THR-1442-C-480 | THR-1442-C-480 | Theracos Sub, LLC | Not Selected | 3 | 2016-07-13 | Details |
| 34 | Toyama Flu 204 | T705aUS204 | Toyama Chemical Co., Ltd | Done - Archived | 2 | 2010-05-21 | Details |
| 94 | Trimel Biopharma Testosterone 03 | Trimel Biopharma SRL | PI Declined | 3 | 2011-09-13 | Details | |
| 69 | TWI Bio DM 2 001 | AC-201-DM-001 | TWI Biotechnology | Done - Archived | 2 | 2011-01-05 | Details |
| 418 | Valneva Vaccine | Valneuva | Not Selected | 2022-05-24 | Details | ||
| 390 | Verily Diabetic Retinopathy 101703 | 101703 | Verily Life Sciences LLC | Done - Archived | Pivotal | 2021-05-25 | Details |
| 283 | Viking NASH VK2809-201 | VK2809-201 | Viking | Done - Archived | 2 | 2016-12-15 | Details |
| 344 | Viking NASH VK2809-202 | VK2809-202 | Viking | Done - Archived | 2B | 2019-08-30 | Details |
| 273 | Visterra Influenza VIS410-202 | VIS410-202 | Visterra Inc. | Done - Archived | 2a | 2016-08-15 | Details |
| 262 | vTv Therapeutics LLC DM | vTv Therapeutics LLC | Not Selected | 2016-02-03 | Details | ||
| 35 | Warner Chilcott 1309 | PR-01309 | Warner-Chilcott Company, LLC | Done - Archived | 3 | 2010-05-21 | Details |
| 36 | Warner Chilcott 1409 | Warner-Chilcott Company, LLC | Done - Archived | 3 | 2010-05-21 | Details | |
| 293 | WB01-202 | Whole Biome | Not Selected | 2017-06-20 | Details | ||
| 37 | Wyeth Depression 4415 | 3151A-4415-NA | Wyeth Pharmaceuticals | Done - Archived | 3 | 2010-05-21 | Details |
| 443 | Xeris Hypothyroid XP-8121-120 | XP-8121-120 | Xeris Pharmaceuticals | Done - Archived | 2 | 2023-03-10 | Details |
| 38 | XOMA Diabetes 2078 | X052078 | XOMA, LLC | Done - Archived | 2 | 2010-05-21 | Details |
| 106 | XOMA HTN 5400 | X985400 | XOMA, LLC | Done - Archived | 3 | 2012-03-28 | Details |
| 318 | Zydus NASH SARO.16.005 | SARO.16.005 | Zydus Discovery DMCC | Done - Archived | 2 | 2018-05-03 | Details |
Studies
My Profile
Account settings and more
My Messages
Inbox and tasks
Settings
Accout Settings
Project
latest tasks and projects
10:10
Morbi quis ex eu arcu auctor sagittis.
by Johne08:40
Proin iaculis eros non odio ornare efficitur.
by Amla07:10
In mattis mi ut posuere consectetur.
by Josef01:15
Morbi quis ex eu arcu auctor sagittis.
by Rima23:12
Morbi quis ex eu arcu auctor sagittis.
by Alaxa10:10
Morbi quis ex eu arcu auctor sagittis.
by Johne08:40
Proin iaculis eros non odio ornare efficitur.
by Amla07:10
In mattis mi ut posuere consectetur.
by Josef01:15
Morbi quis ex eu arcu auctor sagittis.
by Rima23:12
Morbi quis ex eu arcu auctor sagittis.
by Alaxa
